Willow Biosciences incorporates Onyx platform

Photo: Willow Biosciences Inc.

Willow Biosciences incorporated the Onyx Genome Engineering Platform into its strain engineering workflows.

The integrated interface of the benchtop Onyx instrument uses gene editing technology, enabling scientists to perform multiplexed, whole genome CRISPR edits at the push of a button.

The Onyx platform will accelerate Willow’s genetic editing capabilities and throughput and impact timelines for the commercial development of its FutureGrown molecules and subsequent reduction in time to market.

“The future of the synthetic biology economy is dependent on both large and small companies innovating under increasing pressure to deliver better products, faster, and often with less resources. Willow is a great example of how a lean, yet highly innovative organization can rapidly integrate and utilize the Onyx platform,” said Dr. Nandini Krishnamurthy, vice-president of Microbial Business Unit, Inscripta. “We are looking forward to working with the team at Willow to further increase their strain performance while shortening development timelines.”